Skip to main content

Irreversible Blockade von FGFR2-positiven intrahepatischen Cholangiokarzinomen – die FOENIX-CCA2-Studie kommentiert

Irreversible blockade of FGFR2-positive intrahepatic cholangiocarcinoma—a comment on the FOENIX-CCA2 study

This is a preview of subscription content, access via your institution.

Literatur

  1. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36:276–282. https://doi.org/10.1200/JCO.2017.75.5009

    Article  CAS  PubMed  Google Scholar 

  2. Saborowski A, Lehmann U, Vogel A (2020) FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? Ther Adv Med Oncol 12:1758835920953293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J et al (2021) Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 7:1669–1677

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Patrick Sven Plum.

Ethics declarations

Interessenkonflikt

P.S. Plum, I. Gockel, A. Hillmer und H. Alakus geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Plum, P.S., Gockel, I., Hillmer, A. et al. Irreversible Blockade von FGFR2-positiven intrahepatischen Cholangiokarzinomen – die FOENIX-CCA2-Studie kommentiert. Onkologie 29, 366–367 (2023). https://doi.org/10.1007/s00761-023-01335-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-023-01335-8